Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 4Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 630Prostatic Neoplasms 372Neoplasms 305Carcinoma, Non-Small-Cell Lung 215Lung Neoplasms 204Colorectal Neoplasms 176Multiple Myeloma 143Pancreatic Neoplasms 136Leukemia, Myeloid, Acute 128Neoplasm Metastasis 124Brain Neoplasms 117Melanoma 116Ovarian Neoplasms 101Carcinoma, Hepatocellular 101Precursor Cell Lymphoblastic Leukemia-Lymphoma 100Glioblastoma 99Uterine Cervical Neoplasms 97Head and Neck Neoplasms 94Squamous Cell Carcinoma of Head and Neck 93Colonic Neoplasms 82Stomach Neoplasms 80Recurrence 80Rectal Neoplasms 80Urinary Bladder Neoplasms 77Sarcoma 77Carcinoma, Renal Cell 76Triple Negative Breast Neoplasms 75Lymphoma 71Lymphoma, Non-Hodgkin 67Leukemia, Lymphocytic, Chronic, B-Cell 66

Interventions

Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Muscle-Invasive Bladder Carcinoma × Clear all
NCT04506554 2025-07-04

A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer

Fox Chase Cancer Center

Phase 2 Active not recruiting
81 enrolled

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡